Safety and Efficacy of Aneurysms Treated With Endovascular Devices
SEATED
1 other identifier
observational
5,000
1 country
1
Brief Summary
In this project the investigators study the safety and efficacy of the recent endovascular devices used in treatment of brain aneurysms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 15, 2025
CompletedFirst Submitted
Initial submission to the registry
April 15, 2025
CompletedFirst Posted
Study publicly available on registry
September 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 15, 2035
September 16, 2025
April 1, 2025
10 years
April 15, 2025
September 8, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluate predictive factors of aneurysm recurrence after endovascular device embolization (efficacy).
Change of aneurysm from Raymond Roy (RR) classification I into RR II or RR III and correlating this with factors such as smoking.
Done at short-term (30 days) post procedural and long term (up to 5 years) post procedural
Interventions
Aneurysm can be treated by endovascular devices using catheters, Treatment modalities can include coils, stents, flow diverters as well as intrasaccular devices
Eligibility Criteria
Patients with cerebral aneurysms treated with endovascular devices
You may qualify if:
- All patients undergoing endovascular aneurysm treatment.
You may not qualify if:
- All endovascular patients NOT undergoing aneurysm treatment e.g. stents used for stroke treatment; devices and materials used for dAVF, AVM treatments.
- Insufficient background data available e.g., to determine size of aneurysm and device.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kings College Hospital, London
London, United Kingdom
Related Publications (1)
Booth TC, Bassiouny A, Lynch J, Sonwalkar H, Bleakley A, Iqbal A, Minett T, Buwanabala J, Narata AP, Patankar T, Islim FI, Kandasamy N, Balasundaram P, Sciacca S, Siddiqui J, Walsh D, Tolias C, Kailaya-Vasan A, Sultan AA, Abd El-Latif M, Mortimer A, Sastry A. Outcome study of the Pipeline Vantage Embolization Device (second version) in unruptured (and ruptured) aneurysms (PEDVU(R) study). J Neurointerv Surg. 2024 Oct 14;16(11):1136-1144. doi: 10.1136/jnis-2023-020754.
PMID: 38071557BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 15, 2025
First Posted
September 16, 2025
Study Start
January 15, 2025
Primary Completion (Estimated)
January 15, 2035
Study Completion (Estimated)
January 15, 2035
Last Updated
September 16, 2025
Record last verified: 2025-04